The burgeoning field of transthyretin amyloid cardiomyopathy (ATTR-CM), which spurred excitement over a potential $20 billion ...

Right now, that's none other than Eli Lilly (NYSE: LLY). However, others are looking to challenge its dominance. Recent comments from Pfizer 's (NYSE: PFE) CEO, Albert Bourla, suggest it could become ...

CEO Albert Bourla sits down with Yahoo Finance Executive Editor Brian Sozzi to talk about when consumers can expect to see ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

Billionaires and the hedge funds they manage bought millions of Pfizer shares in the third quarter. Shares of Pfizer are down by nearly half since the end of 2022. Pfizer faces significant patent ...

Pfizer Inc. Chief Executive Albert Bourla said the company secured a three-year grace period from President Trump’s promised tariffs on pharmaceuticals in a deal that would lower some of the company’s ...

Shares of prominent vaccine makers Moderna MRNA, BioNTech BNTX, Pfizer PFE, Novavax NVAX and Vaxcyte PCVX fell on Monday after the FDA announced plans to impose strict new vaccine requirements. What’s ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Bothell-based Seagen might be ...

After weeks of deliberation, Pfizer was scolded by a U.K. pharmaceutical industry trade group after its chief executive officer made misleading statements in a media interview about the need to ...